脓毒症生物标记物的研究进展

Research progress of biomarkers in sepsis

全身性炎症反应综合征(SIRS)是临床危重病患者中常见的并发症。根据发病机制可分为感染型SIRS即脓毒症和非感染型SIRS,两者因临床表现相似,诊断标准缺乏特异性,临床施治缺乏针对性,使得SIRS的病死率居高不下。目前临床上以脓毒症最为常见,针对脓毒症早期诊断以及预后判断的生物标记物研究已取得很大进展,其中降钙素原、脂多糖结合蛋白受体以及细胞因子等多种生物标记物在脓毒症的诊断鉴别以及预后中均表现出良好的特异性和灵敏性,对临床治疗脓毒症具有很大的帮助。文章旨在对脓毒症生物标记物的研究进行综述。

Systemic inflammatory response syndrome(SIRS)is a common complication in critically ill patients.According to the pathogenesis,it can be divided into infection SIRS(sepsis)and non-infection SIRS.It is difficult to distinguish sepsis and non-infection SIRS because of the similar clinical manifestations.At present,the mortality caused by SIRS is relatively high because of the unspecific diagnostic criteria anduntargeted clinical treatment.There are many biomarkers studied for early diagnosis and prognosis of sepsis.Biomarkers,such as procalcitonin,Lipopolysaccharides receptor and cytokine,showed good specificity and sensitivity in the diagnosis,identification and prognosis of sepsis,which possessedgreat help in clinical treatment of sepsis.In this paper,several sepsis biomarkers were reviewed.